Rosa Maria Muñoz-Cano

Allergy Service Allergist

Research group

Clinical and experimental respiratory immunoallergy Accredited researcher (R3A)

rmunoz@clinic.cat 0000-0001-8566-8285

Healthcare

Clínic Respiratory Institute
The Respiratory Institute is the area of the Hospital Clínic dedicated to respiratory diseases and allergology.
Pulmonology
The Pulmonology Department forms part of the Clínic Respiratory Institute (ICR) at the Hospital Clínic de Barcelona. It is a national and international reference centre for its quality of care, teaching and research in the field of respiratory disease.
The Department has highly specialized care facilities and programmes that have placed it at the forefront in the field of infectious respiratory diseases, respiratory failure, airway diseases (COPD, asthma, bronchiectasis), sleep-related breathing disorders, pulmonary hypertension, diffuse interstitial lung diseases, and lung cancer.
The Department has an Intensive and Intermediate Respiratory Care Unit, dedicated exclusively to the care of critically ill respiratory patents, a hospital ward, and several complementary examination rooms for respiratory endoscopy and interventional pulmonology, sleep-related breathing disorders and pulmonary haemodynamics.

Featured publications

MRGPRX2-mediated mast cell response to drugs used in perioperative procedures and anaesthesia

Authors:
Navinés-Ferrer, A; Serrano-Candelas, E; Lafuente, A; Muñoz-Cano, R; Martín, M;

Gastaminza, G.

Reference: Scientific Reports 2018.
Mechanisms, Cofactors, and Augmenting Factors Involved in Anaphylaxis

Authors:
Muñoz-Cano, R; Pascal, M; Araujo, G; Goikoetxea, MJ; Valero, AL;

Picado, C; Bartra, J.

Reference: Frontiers In Immunology 2017.
Allergic respiratory disease (ARD), setting forth the basics: proposals of an expert consensus report

Authors:
Navarro, AM; Delgado, J; Muñoz-Cano, RM; Dordal, MT; Valero, A;

Quirce, S.

Reference: Clinical And Translational Allergy 2017.
Effects of rupatadine on Platelet activating factor (PAF)-induced human mast cell degranulation compared with desloratadine and levocetirizine (The MASPAF study)

Authors:
Munoz-Cano, R; Ainsua-Enrich, E; Torres-Atencio, I; Martin, M; Sanchez-Lopez, J;

Bartra, J; Picado, C; Mullol, J; Valero, A.

Reference: Journal Of Investigational Allergology And Clinical Immunology 2017.
Nonsteroidal anti-inflammatory drugs enhance IgE-mediated activation of human basophils in patients with food anaphylaxis dependent and independent of nonsteroidal anti-inflammatory drugs

Authors:
Pascal, M; Munoz-Cano, R; Mila, J; Sanz, M L; Diaz-Perales, A;

(...)

Juan, M; Valero, A; Yague, J; Picado, C; Bartra, J.

Reference: Clinical And Experimental Allergy 2016.
Distinct transcriptome profiles differentiate nonsteroidal anti-inflammatory drug-dependent from nonsteroidal anti-inflammatory drug-independent food-induced anaphylaxis

Authors:
Muñoz-Cano, R; Pascal, M; Bartra, J; Picado, C; Valero, A;

(...)

Brooks, S; Ombrello, M; Metcalfe, DD; Rivera, J; Olivera, A.

Reference: Journal Of Allergy And Clinical Immunology 2016.
Mechanisms of Anaphylaxis Beyond IgE

Authors:
Munoz-Cano, R; Picado, C; Valero, A; Bartra, J;

Reference: Journal Of Investigational Allergology And Clinical Immunology 2016.
Role of Art v 3 in pollinosis of patients allergic to Pru p 3

Authors:
Sánchez-López, J; Tordesillas, L; Pascal, M; Muñoz-Cano, R; Garrido, M;

(...)

Vilella, R; Valero, A; Díaz-Perales, A; Picado, C; Bartra, J.

Reference: Journal Of Allergy And Clinical Immunology 2014.
Lipid transfer protein syndrome: clinical pattern, cofactor effect and profile of molecular sensitization to plant-foods and pollens

Authors:
Pascal, M; Munoz-Cano, R; Reina, Z; Palacin, A; Vilella, R;

(...)

Rueda, M; Salcedo, G; Valero, A; Yaguee, J; Bartra, J.

Reference: Clinical And Experimental Allergy 2012.
Up-Date in Family Medicine. Anaphylaxis, the risk of being underdiagnosed

Authors:
Muñoz-Cano R.; Rueda M.; Cardona V.; Ras R.;

Reference: Semergen 2008.

Featured Projects

Estudio MASPAF: PAPEL DE LOS ANTIHISTAMÍNICOS (DESLORATADINA, RUPATADINA Y LEVOCETIRINA) Y DE LOS ANTAGONISTAS DEL FACTOR DE ACTIVACIÓN PLAQUETAR SOBRE LA ACTIVACIÓN MASTOCITARIA INDUCIDA POR EL FACTOR DE ACTIVACIÓN PLAQUETAR (PAF)

Funder: Grupo Uriach Pharma

Duration: 01/01/2009

Rosa Maria Muñoz-Cano

Research group

Healthcare

Featured publications

Featured Projects

Estudio MASPAF: PAPEL DE LOS ANTIHISTAMÍNICOS (DESLORATADINA, RUPATADINA Y LEVOCETIRINA) Y DE LOS ANTAGONISTAS DEL FACTOR DE ACTIVACIÓN PLAQUETAR SOBRE LA ACTIVACIÓN MASTOCITARIA INDUCIDA POR EL FACTOR DE ACTIVACIÓN PLAQUETAR (PAF)

Subscribe to the Newsletter of Clínic